Establishment Labs Holdings Inc represents a strong set of values and corporate philosophy. The company is dedicated to providing innovative medical technology solutions with a focus on safety and aesthetic outcomes. Their commitment to patient satisfaction is evident in their portfolio of breast and body aesthetic products. Establishment Labs Holdings Inc prioritizes quality, striving to meet rigorous standards and gaining regulatory approvals. With a customer-centric approach, the company aims to deliver state-of-the-art, personalized solutions that elevate patient experiences. By continuously investing in research and development, Establishment Labs Holdings Inc remains at the forefront of the industry, delivering excellence and transforming lives.

Establishment Labs Holdings Inc is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where it is headquartered. Additionally, Establishment Labs Holdings Inc has significant operations in Europe, with a focus on countries like France, Germany, Spain, Italy, and the United Kingdom. The company also has a presence in Latin America, particularly in Brazil, Colombia, Mexico, and Argentina. With its expanding international reach, Establishment Labs Holdings Inc continues to establish its footprint in the global market, driving growth and innovation in the field of medical aesthetics.

Establishment Labs Holdings Inc has achieved significant milestones since its establishment. Some notable achievements include receiving FDA approval for the Motiva Implants® line, which offers cutting-edge technology for breast augmentation and reconstruction. The company has expanded its global presence by securing regulatory approvals in various countries, further enhancing its market reach. Establishment Labs Holdings Inc has also fostered collaborations with renowned plastic surgeons and academic institutions to continually advance its innovative medical solutions. These achievements highlight the company's commitment to revolutionizing the aesthetics industry and improving patient outcomes.

Establishment Labs Holdings Inc is a renowned global medical device company that specializes in breast aesthetics and reconstruction technologies. Founded in 2004, the company has established itself as a leading player in the field, offering innovative products and solutions that cater to the specific needs of patients and healthcare professionals. With a focus on safety, aesthetics, and patient satisfaction, Establishment Labs has earned a strong reputation worldwide. As a publicly traded company, it operates with a commitment to excellence, continually advancing its technologies and expanding its global footprint. With its dedication to quality and innovation, Establishment Labs Holdings Inc continues to make significant contributions to the medical aesthetics industry.

The main competitors of Establishment Labs Holdings Inc in the market include other leading companies in the medical aesthetics industry, such as Allergan Plc, Sientra Inc, and Johnson & Johnson. These companies also offer a range of aesthetic products and solutions, and compete with Establishment Labs in terms of product innovation, market share, and customer base.

Establishment Labs Holdings Inc is primarily active in the aesthetic and medical device industries.

The business model of Establishment Labs Holdings Inc is focused on designing, manufacturing, and marketing medical devices and breast implants for aesthetic and reconstructive surgeries. The company specializes in the Motiva Implant Matrix, a highly innovative and advanced silicone breast implant technology. Establishment Labs aims to provide safe, high-quality, and aesthetically pleasing solutions to meet the evolving needs of surgeons and patients globally. Through continuous research and development, they strive to expand their product portfolio and enhance patient outcomes. With a strong emphasis on innovation and customer satisfaction, Establishment Labs is committed to delivering excellence in the field of aesthetic and reconstructive surgery.

Establishment Labs Holdings KGV ir -16,89.

Establishment Labs Holdings KUV ir 6,07.

AlleAktien kvalitātes vērtējums Establishment Labs Holdings ir 3/10.

gaidāmā Establishment Labs Holdings apgrozījums ir 178,38 milj. USD.

gaidāmā Establishment Labs Holdings peļņa ir -64,09 milj. USD.

Establishment Labs Holdings Inc is a leading company in the medical aesthetics industry. The company's business model is based on the manufacturing and distribution of breast implants, as well as the provision of complementary plastic surgery products and technologies. One of the focuses of Establishment Labs Holdings is the manufacturing of round, anatomically shaped, and textured silicone gel breast implants. These products are sold under the brand Motiva and offer a wide range of sizes and shapes to meet individual patient needs and preferences. Motiva implants are known for their high quality, durability, and safety, and are available in over 70 countries worldwide. In addition to breast implants, Establishment Labs Holdings offers a range of complementary products, including the MatrixChamber mattress overlay manufactured in Full HD technology. This technology is also used in a variety of surgical instruments distributed by the company. The technological advancements achieved by Establishment Labs Holdings can be attributed to its innovative and dedicated team of researchers and developers. The company heavily invests in research and development to create new technologies and products that benefit both patients and physicians. Another important aspect of Establishment Labs Holdings' business model is its collaboration with a network of certified plastic surgeons in various countries. The company offers training and educational opportunities for surgeons interested in using Motiva implants and other products from Establishment Labs Holdings. This ensures that its products are being used by qualified professionals and also provides a high level of customer service and support for patients. In addition to offering medical products and technologies, Establishment Labs Holdings is committed to social responsibility. The company is dedicated to sustainability and environmental friendliness and is certified as carbon-neutral and for sustainable value creation. In summary, the business model of Establishment Labs Holdings Inc is focused on providing high-quality medical products and technologies to plastic surgeons and patients worldwide. Through its focused research and development efforts, collaboration with qualified professionals, and commitment to sustainability, the company is well positioned to meet the constantly evolving needs and demands of the medical aesthetics industry.

Establishment Labs Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Establishment Labs Holdings vai uzņēmums nedod dividendes.

Establishment Labs Holdings ISIN ir VGG312491084.

Establishment Labs Holdings WKN ir A2JRE4.

Establishment Labs Holdings simbols ir ESTA.

Pēdējo 12 mēnešu laikā Establishment Labs Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Establishment Labs Holdings plāno maksāt dividendes 0 USD apmērā.

Establishment Labs Holdings pašreizējā dividendu rentabilitāte ir .

Establishment Labs Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Establishment Labs Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Establishment Labs Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Establishment Labs Holdings apmērā 0 USD, kas tika izmaksāta 1.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.11.2024..

Pēdējās dividendes izmaksa notika 1.11.2024..

Gadā 2023, Establishment Labs Holdings izmaksāja 0 USD dividendes.

Establishment Labs Holdings dividendes tiek izmaksātas USD.